Publicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (47)

2024

  1. ADAMTS13 recovery in acute thrombotic thrombocytopenic purpura after caplacizumab therapy

    Blood, Vol. 143, Núm. 18, pp. 1807-1815

  2. Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC

    Bone Marrow Transplantation

2023

  1. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  2. Expert opinion paper on the treatment of hemophilia a with emicizumab

    Hematology (Amsterdam, Netherlands), Vol. 28, Núm. 1, pp. 2166334

  3. Impact of pre- and/or post-autologous stem cell transplantation exposure to brentuximab vedotin on survival outcomes in patients with high-risk Hodgkin lymphoma

    Annals of Hematology, Vol. 102, Núm. 2, pp. 429-437

  4. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  5. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

  3. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  4. Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa

    Expert Opinion on Biological Therapy, Vol. 21, Núm. 9, pp. 1165-1171

  5. Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura

    Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573

  6. The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study

    European Journal of Haematology, Vol. 106, Núm. 3, pp. 371-379

  7. Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project

    Haemophilia, Vol. 27, Núm. 6, pp. 1007-1021

2020

  1. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

  2. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019